Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2010 1
2013 4
2014 3
2016 1
2017 2
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. Giovannoni G, et al. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089960 Free article. Clinical Trial.
LSN MS guidelines for the management of multiple sclerosis.
Shatila AR, Koussa S, Jabbour R, Mourad A, Aouad A, Sabbagh G, Kallab K, Hilal R, Khalifeh R, Gebeily S, Tourbah A; Lebanese Society of Neurology. Shatila AR, et al. Among authors: gebeily s. Rev Neurol (Paris). 2013 Dec;169(12):950-5. doi: 10.1016/j.neurol.2012.12.002. Epub 2013 Feb 19. Rev Neurol (Paris). 2013. PMID: 23434141 Review.
A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting.
Karussis D, Biermann LD, Bohlega S, Boiko A, Chofflon M, Fazekas F, Freedman M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Miller A; International Working Group for Treatment Optimization in MS. Karussis D, et al. Among authors: gebeily s. Eur J Neurol. 2006 Jan;13(1):61-71. doi: 10.1111/j.1468-1331.2006.01147.x. Eur J Neurol. 2006. PMID: 16420394 Review.
Biosimilars: opinion of an expert panel in the Middle East.
Bohlega S, Al-Shammri S, Al Sharoqi I, Dahdaleh M, Gebeily S, Inshasi J, Khalifa A, Pakdaman H, Szólics M, Yamout B. Bohlega S, et al. Among authors: gebeily s. Curr Med Res Opin. 2008 Oct;24(10):2897-903. doi: 10.1185/03007990802381554. Epub 2008 Sep 2. Curr Med Res Opin. 2008. PMID: 18768104 Review.
Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis.
Goodin DS, Biermann LD, Bohlega S, Boiko A, Chofflon M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Karussis D, Miller A, Pakdaman H, Selmaj K, Sharief M; International Working Group for Treatment Optimization in MS. Goodin DS, et al. Among authors: gebeily s. Curr Med Res Opin. 2007 Nov;23(11):2823-32. doi: 10.1185/03007x233007. Curr Med Res Opin. 2007. PMID: 17908370 Review.
Multiple sclerosis in the Levant: a regional consensus statement.
Yamout B, El-Salem K, Gebeily S, Khoury S, Abu Zeid N, Hamoulila K, Alhalabi MS, Hasan ZN, Al Hamadani H, Hamoodi H, Al Omar A, Dahdaleh M. Yamout B, et al. Among authors: gebeily s. Int J Neurosci. 2014 May;124(5):377-82. doi: 10.3109/00207454.2013.833198. Epub 2013 Sep 13. Int J Neurosci. 2014. PMID: 23927564
Head and facial injuries due to cluster munitions.
Fares Y, Fares J, Gebeily S. Fares Y, et al. Among authors: gebeily s. Neurol Sci. 2014 Jun;35(6):905-10. doi: 10.1007/s10072-013-1623-2. Epub 2014 Jan 4. Neurol Sci. 2014. PMID: 24389857
15 results